Phosplatin Therapeutics is a clinical stage pharmaceutical company developing phosphaplatins, a family of small-molecule compounds designed to replace conventional cytotoxic therapies in the treatment of cancer.
Phosphaplatins are the result of decades of research by the inventor. Our lead compound, PT-112, is the subject of an ongoing first-in-human Phase I Clinical study.
1350 Avenue of the Americas 3rd Fl.
New York, NY 10019-4703